GSK plc (GSK,GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include adults aged 18 to 49 years at increased risk for RSV disease. GSK's RSV vaccine was previously approved in Japan for the prevention of RSV disease in all adults aged 60 years and older, and for adults aged 50-59 AIR for RSV disease.
The company said the approval was supported by data from a Phase IIIb trial demonstrating a non-inferior immune response in adults aged 18 to 49 years AIR for RSV disease compared to adults aged 60 years and above.
The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics, a subsidiary of Agenus Inc.
At last close, GSK plc shares were trading at 1,859.50 pence, down 0.16%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.